[go: up one dir, main page]

EP1255848A2 - Procedes visant a augmenter la production de cytokines dans une culture cellulaire - Google Patents

Procedes visant a augmenter la production de cytokines dans une culture cellulaire

Info

Publication number
EP1255848A2
EP1255848A2 EP00951042A EP00951042A EP1255848A2 EP 1255848 A2 EP1255848 A2 EP 1255848A2 EP 00951042 A EP00951042 A EP 00951042A EP 00951042 A EP00951042 A EP 00951042A EP 1255848 A2 EP1255848 A2 EP 1255848A2
Authority
EP
European Patent Office
Prior art keywords
cytokine
expression
cells
pkr
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00951042A
Other languages
German (de)
English (en)
Inventor
Allan S. Lau
Laura Browning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetrol Biotherapeutics Inc
Original Assignee
Genetrol Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetrol Biotherapeutics Inc filed Critical Genetrol Biotherapeutics Inc
Publication of EP1255848A2 publication Critical patent/EP1255848A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Definitions

  • the present invention relates to methods for enhancing the production of cytokines in cell culture by the over-expression of PKR.
  • dsRNA-activated protein kinase PLR
  • Pl/elF2 kinase DAI or dsl for dsRNA-activated inhibitor
  • p68 human or p65 (murine) kinase
  • Pl/elF2 kinase DAI or dsl for dsRNA-activated inhibitor
  • p68 human or p65 (murine) kinase
  • PKR has been shown to play a variety of important roles in the regulation of translation, transcription, and signal transduction pathways through its ability to phosphorylate protein synthesis initiation factor eIF2, and I-kappaB (the inhibitor of NF-kappaB; Kumar A, et al, 1994), in addition to other substrates.
  • PKR eukaryotic initiation factor-2
  • Activities attributed to PKR include a role in (1) mediating the antiviral and anti- proliferative activities of IFN-alpha and IFN-beta, (2) the response of uninfected cells to physiologic stress, and (3) cell growth regulation (Clemens MJ and Elia A, 1997; Zamanian-
  • PKR may function as a tumor suppressor and inducer of apoptosis.
  • Clemens MJ and Bommer UA 1999; Yeung, Lau et al, 1996; Koromilas et al. , 1992
  • expression of an active form of PKR triggers apoptosis, possibly through upregulation of the Fas receptor (Donze O, et al, 1999).
  • interferon family of proteins are prototypes of cytokines and have been shown to play key roles in immune defense against pathogens and cancerous tissues.
  • Cytokines are regulatory molecules which exhibit a range of biological activities and act on a wide range target cells. (See, e.g., Balkwill FR and Burke F, 1989; Wong G and Clark
  • cytokines are currently produced by the expression of recombinant proteins in insect, bacterial and mammalian host cells.
  • Cytokines are produced for various therapeutic applications by either purifying the natural cytokine from mammalian cell lines or recombinantly producing the cytokine in insect, microbial or mammalian cells.
  • Natural cytokines are preferable in that they are known to contain the full repertoire of native forms of a given cytokine and have the proper structure, but they are expensive and time-consuming to produce.
  • Recombinantly produced cytokines are less expensive to make, but dependent upon the source may contain foreign antigens, resulting in an immune response by the subject to which they are administered, or may be less active due to structural variation from the native form, i.e., glycosylation pattern.
  • a method for enhancing the production of natural cytokines to make them less expensive to produce would be advantageous.
  • Present methods utilize expression of cytokines in microbial systems, which do not permit the glycosylation and native folding of the cytokine proteins, or in human cells that generally produce very low levels of recombinant protein.
  • the present invention is directed to the surprising discovery that by manipulating the expression of certain genes, cytokine production is enhanced in cultured mammalian cells.
  • the invention provides methods for enhanced production of cytokines in mammalian cell culture by providing cell lines in which the expression of a cytokine regulatory protein is increased to above-normal levels, resulting in an increase in cytokine production.
  • the invention provides a method for producing a cytokine by culturing a mammalian cell line that has been modified in an manner to result in overexpression of a cytokine regulatory factor and treated to effect cytokine production, followed by collection of the cytokine produced by the cultured, treated cell line.
  • the cytokine regulatory factor is PKR.
  • the mammalian cell line is transfected with an expression vector having a promoter fragment which functions in the host cell, operably linked to a DNA segment encoding a cytokine regulatory factor, such that the cytokine regulatory factor is overexpressed in the cell line.
  • the cell line may be treated by priming and inducing to effect cytokine production, e.g. by priming with a phorbol ester, such as phorbol myristate acetate (PMA), and by inducing with a dsRNA such as poly r(I):poly r(C).
  • Priming is a well known phenomenon whereby pretreatment of cells with a cytokine or other compound results in enhanced production of the same and/or additional cytokines following subsequent stimulation.
  • Exemplary cytokines the expression of which may be increased using the methods of the invention include, but are not limited to, interleukins (IL-l ⁇ IL-l ⁇ , IL-lra, IL-2 and IL-4 through 8), tumor necrosis factors alpha and beta (TNF- ⁇ ), the colony stimulating factors (granulocyte colony stimulating factor, G-CSF; granulocyte-macrophage colony stimulating factor, GM-CSF; and IL-3), the angiogenic factors (fibroblast growth factor, FGF; vascular endothelial growth factor, VEGF; and platelet-derived growth factors 1 and 2 (PDGF- 1 and -2) and the anti-angiogenic factors (angiostatin and endostatin).
  • interleukins IL-l ⁇ IL-l ⁇ , IL-lra, IL-2 and IL-4 through 8
  • TNF- ⁇ tumor necrosis factors alpha and beta
  • the colony stimulating factors granulocyte colony stimulating factor, G-CSF
  • the cytokines may be expressed under the control of an inducible promoter, e.g., a metallothionein promoter or a tetracycline (TRE) promoter; or a constitutive promoter, e.g., a CMV promoter.
  • the invention further provides cell line compositions characterized by above normal expression of a cytokine regulatory factor, e.g., PKR, and above normal expression of a cytokine, e.g., interleukin 6 (IL-6), interleukin 8 (IL-8) or tumor necrosis factor beta (TNF- ⁇ ).
  • a cytokine regulatory factor e.g., PKR
  • a cytokine e.g., interleukin 6 (IL-6), interleukin 8 (IL-8) or tumor necrosis factor beta (TNF- ⁇ ).
  • IL-6 interleukin 6
  • IL-8 interleukin 8
  • TNF- ⁇ tumor necrosis factor beta
  • Figure 1 illustrates interleukin-6 (IL-6) production in untransformed Namalwa and
  • PKR-overexpressing Namalwa cells 2A1.Dl .G7 and parental Namalwa cells were cultured in DMEM/F12 medium containing 20 nM PMA for 20 hr followed by treatment with 200 ⁇ g/ml poly r(I):r(C) for 3 days (+), or left untreated (-). Culture supernatants were collected and analyzed for IL-6 production by ELISA (R&D Systems), according to the procedure provided by the supplier.
  • FIG. 2 illustrates interleukin-8 (IL-8) production in untransformed Namalwa and PKR-overexpressing Namalwa cells, following the same procedure set forth in the description for Figure 1, except that the culture supernatants were analyzed for IL-8 production by ELISA according to the procedure provided by the supplier of the ELISA kits (R&D Systems).
  • Figure 3 illustrates tumor necrosis factor ⁇ (TNF- ⁇ ) production in untransformed
  • Namalwa and PKR-overexpressing Namalwa cells following the same procedure set forth in the description for Figure 1, except that the culture supernatants were analyzed for TNF- ⁇ production by ELISA according to the procedure provided by the supplier of the ELISA kits (R&D Systems).
  • vector refers to a nucleotide sequence that can assimilate new nucleic acids, and propagate those new sequences in an appropriate host.
  • Vectors include, but are not limited to recombinant plasmids and viruses.
  • the vectors (e.g., plasmid or recombinant virus) of the invention can be in a carrier, for example, a plasmid complexed to a protein, a plasmid complexed with lipid-based nucleic acid transduction systems, or other non-viral carrier systems.
  • An expression vector may comprise additional elements, for example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a prokaryotic host for cloning and amplification.
  • Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. Further, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences that flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art.
  • Expression and cloning vectors typically contain a selectable marker gene, which encodes a protein that (a) confers resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complements auxotrophic deficiencies, or (c) supplies critical nutrients not available from complex media, e.g. , the gene encoding D-alanine racemase for Bacilli.
  • a nucleic acid coding sequence must be "operably linked" by placing it in a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • "operably linked" DNA sequences are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism.
  • the control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site.
  • Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
  • promoter sequences encode either constitutive or inducible promoters.
  • the promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters combine elements of more than one promoter, are generally known in the art, and are useful in practicing the present invention.
  • cytokine regulatory factor expression refers to transcription and translation of the cytokine regulatory factor gene, the products of which include precursor RNAs, mRNAs, polypeptides, post-translation processed polypeptides, and derivatives thereof, including cytokine regulatory factors from other non-human species such as murine or simian enzymes.
  • PTK expression refers to transcription and translation of a PKR gene, the products of which include precursor RNAs, mRNAs, polypeptides, post- translation processed polypeptides, and derivatives thereof, including PKRs from other non- human species such as murine or simian enzymes.
  • biological activity of PKR and “biologically active PKR” refer to any biological activity associated with PKR, or any fragment, derivative, or analog of PKR, such as enzymatic activity, specifically including autophosphorylation activity, eukaryotic translation initiation factor 2 (eIF-2) phosphorylation activity, or kinase activity resulting in enhanced transcription of protein such as cytokines. It follows that the biological activity of a given cytokine regulatory factor refers to any biological activity typically attributed to that factor by those of skill in the art.
  • normal level of cytokine regulatory factor activity As used herein, the terms "normal level of cytokine regulatory factor activity”, “normal level of cytokine regulatory factor expression”, exemplified by “normal level of PKR activity” and “normal level of PKR expression” refer to the level of cytokine regulatory factor, e.g., PKR activity or expression, determined to be present in unstimulated or uninfected cells of a particular type, e.g., a particular cell line.
  • cytokine regulatory factor activity or expression is reported as a range of cytokine regulatory factor activity or expression which is generally observed for a given type of cells which are not transfected with a vector encoding the cytokine regulatory factor, unstimulated (not induced or primed) and uninfected and may vary somewhat dependent upon culture conditions.
  • the U937 cell line may have a normal range of PKR activity which differs from the normal range of PKR activity for the U937, T98G or Namalwa cell lines.
  • over-expression of a given cytokine regulatory factor e.g., PKR
  • PKR cytokine regulatory factor
  • over-expression of a given cytokine regulatory factor, e.g., PKR means an expression level which is above the normal range of PKR expression generally observed for a given type of cells which are not transfected with a vector encoding PKR, unstimulated (not induced, pretreated, or primed) and uninfected.
  • normal level of cytokine activity and “normal level of cytokine expression” refer to the level of cytokine activity or expression, determined to be present in cells of a particular type which do not overexpress a given cytokine regulatory factor, e.g., PKR, such as an untransfected cell line which either normally produces or is capable of producing a given cytokine.
  • PKR cytokine regulatory factor
  • a given cell line which does not overexpress PKR may have a normal range of cytokine activity which differs from the range of cytokine activity for that same cell line following transfection with, and over-expression of, PKR.
  • the present invention is based on the discovery that the level of cytokine production in mammalian cell culture can be increased by control of the expression or activity of certain proteins that normally regulate cytokine expression in vivo.
  • cytokine-specific regulatory factors for example interferon regulatory factors (IRF-1, IRF-3 and IRF-7), cytokine receptors, nuclear factor KB (NF-KB), activator protein- 1 (AP-1), nuclear factor IL-6 (NF-IL6), protein kinase C, p38 MAPK, STAT/Jak kinase system factors, and in particular PKR.
  • Enhancing the expression or activity of any of these regulatory factors will result in a higher than normal level of expression of the genes which encode one or more cytokines. Such enhanced cytokine expression will result in more efficient and lower cost production of cytokines.
  • PKR is used herein as an example of a protein capable of regulating cytokine expression, however it will be understood that other cytokine regulatory factors may be used in place of PKR, e.g., PMA, protein kinase C (PKC) inducers, interferon- ⁇ , interferon- ⁇ , interferon- ⁇ , TNF- ⁇ , GM-CSF, EGF and PDGF.
  • PMA protein kinase C
  • PLC protein kinase C
  • interferon- ⁇ interferon- ⁇
  • TNF- ⁇ TNF- ⁇
  • GM-CSF GM-CSF
  • EGF EGF
  • cytokine regulatory factor e.g., PKR
  • Mammalian cell cultures which express a higher constitutive level of the cytokine regulatory factor, or in which cytokine regulatory factor expression can be induced to higher levels are therefore useful for the production of cytokines.
  • the method relies on the use cells that overexpress a protein capable of regulating cytokine expression (a cytokine regulatory factor), e.g., including, but not limited to PKR, as the source of cytokines, with no particular method of cytokine regulatory factor over- expression required except that typically a non-microbial inducer is used.
  • a cytokine regulatory factor e.g., including, but not limited to PKR
  • viral induction e.g., together with sodium butyrate treatment is used.
  • the method comprises (a) culturing mammalian cells capable of over- expression of the cytokine regulatory factor or an analog or homologue thereof under conditions sufficient to overexpress the cytokine regulatory factor, and (b) treating the cell culture as appropriate to induce the expression of a cytokine gene.
  • the cells used to produce a given cytokine can overexpress a cytokine regulatory factor, e.g., PKR from any mammalian source, such as the PKR normally found in rabbit reticulocytes, various mouse tissues, or human peripheral blood mononuclear cells.
  • a cytokine regulatory factor e.g., PKR from any mammalian source, such as the PKR normally found in rabbit reticulocytes, various mouse tissues, or human peripheral blood mononuclear cells.
  • a cytokine regulatory factor e.g., PKR from any mammalian source, such as the PKR normally found in rabbit reticulocytes, various mouse tissues, or human peripheral blood mononuclear cells.
  • murine p65 kinase Freng, G.S et ⁇ /.,1992
  • human p68 kinase Meurs, E et al, 1990; GenBank Accession No. NM_002759
  • the cytokine regulatory factor which is overexpressed is an analog of a native cytokine regulatory factor, e.g., a PKR analog such as a non-natural protein kinase that can mediate dsRNA activation of cytokine transcription (usually obtained by modification of the gene encoding a native PKR protein).
  • a PKR analog such as a non-natural protein kinase that can mediate dsRNA activation of cytokine transcription (usually obtained by modification of the gene encoding a native PKR protein).
  • Mammalian cells capable of overexpressing a cytokine regulatory factor may be obtained by any of a number of methods, that are well known in the art or may be obtained from commercial sources.
  • Exemplary methods for obtaining cytokine regulatory factor-overexpressing cells include selection for cells that express higher levels of the cytokine regulatory factor, transfection with an expression vector encoding the cytokine regulatory factor under control of a promoter, and other methods which result in an increase in expression of the cytokine regulatory factor over normal levels.
  • Additional approaches include inactivation or decreasing the levels of the PKR- inhibiting factor, p58 which normally inhibits PKR activity. Mutation, modification or gene- targeting ablation of p58 will result in enhanced PKR activity (Barber, G.N. et al, 1994).
  • Another example includes natural, synthetic or recombinant activators of PKR that can enhance the expression of PKR, e.g. the PKR activator protein, PACT (Patel, R.C. and Sen, G.C., 1998).
  • the present invention provides vectors suitable for the transformation of human cells, e.g., recombinant expression vectors containing a polynucleotide which encodes a protein effective to regulate cytokine expression operably linked to regulatory elements effective for expression of the protein in a mammalian cell line.
  • Preferred coding sequences include the coding sequence for p68 (human) or p65 (murine) kinase.
  • the invention includes a mammalian host cell containing the vector.
  • the vector includes a polynucleotide sequence which encodes a protein effective to regulate cytokine expression together with additional coding sequences, such as fusion protein or signal peptide coding sequences, in combination with non- coding sequences, such as introns and control elements, such as promoter and terminator elements or 5' and/or 3' untranslated regions, effective for expression of the coding sequence in a suitable host, and/or in a vector or host environment in which the coding sequence is a heterologous gene.
  • heterologous DNA and “heterologous gene” is meant nucleotides that are not endogenous to the cell or part of the genome in which they are present.
  • the expression vector also contains a ribosome binding site for translation initiation, and a transcription terminator.
  • the vector may also include appropriate sequences for amplifying expression.
  • the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells.
  • Exemplary promoters include both constitutive promoters and inducible promoters, examples of which include a CMV promoter, an SV40 early promoter, an RSV promoter, an EF-l ⁇ promoter, a promoter containing the tet responsive element (TRE) and the metallothienein promoter.
  • a heterologous nucleic acid sequence which contains the coding sequence for a protein effective to regulate cytokine expression may be included in any one of a variety of expression vectors for expressing a polypeptide. Any vector may be used as long as it is replicable and viable in the mammalian cells into which it is introduced.
  • the appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by standard procedures. Such procedures and related sub-cloning procedures are deemed to be within the scope of knowledge of those skilled in the art.
  • the vector containing the appropriate DNA sequence as described above, as well as an appropriate promoter or control sequence, may be employed to transform a mammalian cell line to permit the cells to express the protein and thereby enhance cytokine production.
  • Introduction of the vector into a host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofectamine or lipofection-mediated transfection, or electroporation (Davis, L., Dibner, M., and Battey, I. Basic Methods in Molecular Biology, 1986).
  • stable expression is preferred. It follows that any method effective to generate stable transformants may be used in practicing the present invention.
  • the invention also provides host cells which have been transduced, transformed or transfected with an expression vector of the invention.
  • the culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those skilled in the art.
  • cytokine-regulating factor examples include, but are not limited to Namalwa, U937, Vero, MRC-5, WI-38 cells, Flow 1000 cells, Flow 4000 cells, FS-4 and FS-7 cells, MG-63 cells, CCRF-SB cells , CCRF-CEM cells and T98G cells.
  • cytokine-regulating factor examples include, but are not limited to cells of the monocyte/macrophage lineage, lymphocytic lineage cells including T- and B-cells, mast cells, fibroblasts, bone marrow cells, keratinocytes, osteoblast derived cells, melanocytes, endothelial cells, platelets, various other immune system cells, lung epithelial cells, pancreatic parenchmal cells, glial cells and tumor cells derived from such cell types.
  • monocyte/macrophage lineage including T- and B-cells, mast cells, fibroblasts, bone marrow cells, keratinocytes, osteoblast derived cells, melanocytes, endothelial cells, platelets, various other immune system cells, lung epithelial cells, pancreatic parenchmal cells, glial cells and tumor cells derived from such cell types.
  • the cytokine-regulating factor-overexpressing cell culture will be inducible for over-expression of the cytokine-regulating factor in order to regulate the level of the factor available for cytokine induction.
  • cytokine-regulating factor activity or expression is reported as a range of cytokine-regulating factor activity or expression, which is generally observed for a given type of cells which have not been transfected with a vector encoding the cytokine-regulating factor, are unstimulated (not induced or primed) and uninfected. It will be understood that the range of normal cytokine-regulating factor activity will vary dependent upon the particular factor, cell type and for a given cell type may vary somewhat dependent upon culture conditions.
  • Higher than normal level preferably means at least 150%, more preferably at least 200 or 300%, most preferably at least 500%, of the normal level for a given cytokine-regulating factor under the particular culture conditions employed.
  • the cytokine-regulating factor- overexpressing cell culture may be constitutive for over-expression of the cytokine-regulating factor or inducible for over-expression of the cytokine-regulating factor.
  • the cytokine-regulating factor is PKR and the PKR- overexpressing cell culture is inducible for PKR over-expression in order to regulate the level of PKR available for cytokine induction.
  • PKR a number of known cell types are useful for making a PKR-overexpressing cell line, with particular examples provided above.
  • assays for PKR expression include autophosphorylation assays, assay for eIF2 ⁇ phosphorylation, Western blot analysis for protein levels and Northern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCR) for PKR mRNA.
  • steps are taken to enhance expression of cytokines by mammalian cells.
  • steps include one or more of ( 1 ) culturing the transfected cells under conditions effective to enhance expression of the cytokine-regulating factor, (2) priming the cytokine- regulating factor-expressing cells with reagents including but not limited to polypeptides, chemicals, or nucleic acids, and (3) treating the cytokine-regulating factor-expressing cells to induce cytokine production (induction).
  • Priming may include treating with a priming agent, e.g., phorbol myristate acetate (PMA) and other phorbol esters, calcium ionophores, interferon- ⁇ , interferon- ⁇ , interferon- ⁇ , G-CSF, GM-CSF, PDGF, TGF, EGF, sodium butyrate, a kinase activator or a transcription activator.
  • a priming agent e.g., phorbol myristate acetate (PMA) and other phorbol esters, calcium ionophores, interferon- ⁇ , interferon- ⁇ , interferon- ⁇ , G-CSF, GM-CSF, PDGF, TGF, EGF, sodium butyrate, a kinase activator or a transcription activator.
  • a priming agent e.g., phorbol myristate acetate (PMA) and other phorbol esters, calcium ionophores, interferon
  • Treating may include adding a microbial (i.e., viral) or non-microbial inducer to the cell culture.
  • the inducer will be a non-microbial inducer, e.g., poly(I):poly(C) or poly r(I):poly r(C).
  • U937 cells are preferred for production of FGF and sTNF-R; Jurkat cells are preferred for production of IL-3 and TNF- ⁇ ; fibroblasts are preferred for production of FGF and angiostatin; U937 cells are preferred for production of IL-6 and homologs thereof; CD-4 expressing cells including Jurkat and HUT are preferred for production of TNF- ⁇ ; and T and B- cells including Jurkat and Namalwa are preferred for production of IL-8 and homologs thereof.
  • Exemplary procedures suitable for such purification include the following: antibody-affinity column chromatography, ion exchange chromatography; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; and gel filtration using, for example, Sephadex G-75.
  • Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, METHODS IN ENZYMOLOGY, 182, 1990; Scopes, PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, Springer- Verlag, New York, 1982.
  • the purification step(s) selected will depend, for example, on the nature of the production process used and the particular cytokine produced.
  • a combination of culture conditions, priming and treating results in significantly enhanced cytokine production, e.g., an increase of at least 2.5-fold, and preferably an increase of 10 fold or greater.
  • the methods of the invention result in an increase in cytokine production that is 100 to 1000 fold or more. Problems typically associated with production of cytokines in cell culture, for example low yield from non-recombinant mammalian systems, improper glycosylation, or misfolding of proteins produced in microbial systems are eliminated in the methods of the present invention, which should prove to be useful for the development of therapeutic proteins.
  • Cytokines Cytokines elicit their biological activities by binding to their cognate receptors followed by signal transduction leading to stimulation of various biochemical processes. In some cases, the expression of such receptors is regulated by specific signals, for example a cytokine may be involved in positive or negative feedback loops and thereby regulate the expression of the receptor for the same or a different cytokine. Such receptors may be the same type of cell that produces the cytokine or a different type of cell.
  • Cytokines serve to mediate and regulate immune and inflammatory responses. In general, cytokine production is transient and production takes place during a short period of transcription resulting in production of mRNA transcripts which are also short-lived and subject to post-transcriptional control mechanisms. Recent studies have indicated that a common signal transduction pathway, the "Jak/STAT" pathway, is used by a variety of cytokines (Abbas, AK, et al, 1997).
  • cytokine capable of production by multiple diverse types of cells.
  • a given cytokine (1) may act on more than one type of cells, (2) may have more than one effect on the same cell, (3) may have an activity shared with another cytokine, and (4) may influence the synthesis or effect of other cytokines, e.g., by antagonizing, or synergizing the effects thereof.
  • sTNF-R Recombinant soluble-tumor necrosis factor receptor
  • Target cells for production of sTNF-R include cells of the monocyte/macrophage lineage.
  • Interleukin-2 or "T-cell growth factor” is known to promote T-cell growth and function.
  • T helper lymphocytes have been activated by stimulation with certain mitogens or interaction of the T cell receptor complex with antigen/MHC complexes on the surface of antigen-presenting cells, IL-2 and IL-2 receptors are induced resulting in clonal expansion of antigen-specific T cells.
  • IL-2 is currently produced by the expression of recombinant IL-2 protein in various types of cells.
  • Target cells for production of IL-2 include T-cells.
  • IL-2 has been implicated as a stimulatory factor in the formation of a number of types of hematopoietic cells, including granulocytes, macrophages, eosinophils, mast cells, megakaryocytes and erythroid cells.
  • IL-3 Interleukin-3
  • IL-3 has been observed to have multiple hematopoietic effects on bone marrow (BM) stem cells, which are more pleiotropic than G-CSF.
  • IL-3 is currently produced using recombinant DNA technology.
  • Target cells for production of IL-3 include T-cells and mast cells.
  • Clinical utilities for IL-3 include applications to: (1) T- and stem cell expansion ex vivo, (2) post-BM transplant in vivo, (3) bone marrow failure (chemotherapy), (4) blood dyscrasia and (5) pancytopenia, in addition to various research uses.
  • Interleukin-4 also known as B cell stimulating factor, or BSF-1 has been observed to have numerous biological effects including, (1) co-stimulation of T cells, mast cells, granulocytes, megakaryocytes, and erythrocytes, (2) induction of the expression of class II major histocompatibility complex molecules on resting B cells, (3) enhanced secretion of IgE and IgGl isotypes by stimulated B cells, and (4) anti-inflammatory properties.
  • IL-4 has been observed to have effects on type 2 helper T-cell (TH2) responses and anti-growth properties.
  • IL-4 is currently produced by expression as a recombinant protein.
  • Target cells for production of IL-4 include T-cells and mast cells.
  • Clinical utilities for IL-4 include applications to stem cell expansion ex vivo, anti- cancer strategies and treatment of solid tumors, in addition to various research uses.
  • Interleukin-5 (IL-5), is proposed to have effects on suppression of allergic responses, and suppression of eosinophils.
  • IL-5 is currently produced by expression as a recombinant protein.
  • Target cells for production of IL-5 include T-cells and mast cells.
  • Clinical utilities for IL-5 include applications in treatment of asthma, in addition to various research uses.
  • Interleukin-6 is a multi-functional cytokine produced by various types of cells, and acts as a differentiation and growth factor on various types of cells including cells in the immune system, hepatocytes, kidney cells, hematopoietic staminal cells, keratinocytes and neurons.
  • IL-6 has been observed to play a role in inflammation, and have to anti-growth properties.
  • IL-6 is currently produced by expression as a recombinant protein.
  • Target cells for production of IL-6 include fibroblasts, T-cells and cells of the monocyte/macrophage lineage.
  • IL-6 Interleukin-7
  • IL-7 previously known as "lymphopoietin-1"
  • B220+ cells pre-B cells derived from long-term bone marrow culture
  • IL-7 has been observed to stimulate the growth of B- and T-cell progenitors in bone marrow, and to play a role in ( 1 ) cytokine synthesis in the skin, (2) increased cytotoxic T lymphocyte (CTL) activity, and (3) increased natural killer (NK) cell activity.
  • CTL cytotoxic T lymphocyte
  • NK natural killer
  • Target cells for production of IL-7 include bone marrow cells and keratinocytes.
  • Clinical utilities for IL-7 include applications to the treatment of melanoma, in addition to various research uses.
  • Interleukin- 8 is a chemotactic cytokine, capable of causing degranulation of human neutrophils and produced by keratinocytes, epithelial cells, synoviocytes, hepatocytes, monocytes and neutrophils.
  • the biological effects of IL-8 have been described as mediated through seven transmembrane domain, G-protein-coupled receptors.
  • IL-8 has been observed to be a member of the CXC chemokine family, and to have chemotactic and angiogenic properties. IL-8 is currently produced by expression as a recombinant protein.
  • Target cells for production of IL-8 include fibroblasts, T-cells and cells of the monocyte/macrophage lineage.
  • IL-8 Although clinical studies have not been completed, predicted utilities for IL-8 include applications to the treatment of bacterial and viral infections, in cancer therapy and in promoting vessel growth, in addition to various research uses.
  • TNF- ⁇ Tumor necrosis factor-alpha
  • TNF- ⁇ tumor necrosis factor beta
  • TNF- ⁇ lymphotoxin
  • TNF- ⁇ has numerous biological functions, including hemorrhagic necrosis of transplanted tumors, cytotoxicity, an important role in endotoxic shock and in inflammatory, immunoregulatory, proliferative, and antiviral responses.
  • TNF-alpha and TNF-beta share a similar spectrum of biological activities.
  • TNF- ⁇ shows anticellular activity on neoplastic cell lines but not on primary cell cultures and normal cell lines, suggesting that it has potent anti-tumor activity.
  • TNF-beta also plays an important role in lymphoid organ development.
  • TNF- ⁇ and TNF- ⁇ bind to the same cell surface receptors consistent with their similar activities.
  • Clinical utilities of TNF- ⁇ and TNF- ⁇ include anti-cancer applications particularly in combination with other chemotherapeutic agents or with gene therapy. Combination therapy may be important so that a relatively low dose of TNF can be administered (U.S. Patent No. 5,976,800 issued 11/2/99).
  • the agents may be useful for treatment of patients with disseminated tumors including melanoma, osteosarcoma, breast carcinoma, and lymphomas.
  • Granulocvte colony-stimulating factor (G-CSF) has been observed to stimulate the proliferation and differentiation of neutrophil precursors and to play a role in granulocyte maturation and oxidative bursts.
  • G-CSF is currently produced by expression as a recombinant protein in bacterial and mammalian host cells.
  • Target cells for the production of G-CSF include fibroblasts, endothelial cells and cells of the monocyte/macrophage lineage.
  • Clinical utilities for G-CSF include application to the treatment of post-chemotherapy pancytopenia, treatment following bone marrow transplantation, and various research uses.
  • Granulocvte-macrophage colony-stimulating factor has been observed to stimulate the production of colonies of granulocytes and macrophages from their precursor cells and to promote the growth and differentiation of pluripotent progenitor cells.
  • GM-CSF appears to play an effector role in granulocyte and macrophage functions.
  • GM-CSF is currently produced by expression of recombinant protein in bacterial and mammalian host cells.
  • Target cells for production of GM-CSF include fibroblasts, endothelial cells and T- cells.
  • Clinical utilities for GM-CSF include broad application to the treatment of post- chemotherapy pancytopenia, treatment following bone marrow transplantation, and various research uses.
  • Fibroblast growth factor both acidic & basic forms, have been observed to play a role in angiogenesis and endothelial cell proliferation. Studies with recombinant FGF-5 in culture indicate that it can promote the survival of cultured motor neurons, indicating that FGF- 5 is a neurotrophic factor of motor neurons.
  • FGF is currently produced by expression as a recombinant protein.
  • Target cells for production of FGF include platelets, endothelial cells and cells of the macrophage lineage.
  • Utilities for FGF include application to the treatment of ischemic heart disease, congestive heart failure, and various condition involving the inflammatory response, as well as to various research uses.
  • VEGF Vascular Endothelial Growth Factor
  • VEGF is currently produced by expression of the recombinant protein in microbial and mammalian host cells.
  • Target cells for production of VEGF include various immune cells.
  • Utilities for VEGF include applications to the treatment of congestive heart failure, in addition to various research uses.
  • Platelet-derived growth factor (PDGF- 1 and PDGF-2). have been observed to act as growth factors and to play a role in angiogensis.
  • Purified human platelet-derived growth factor (PDGF) has been shown to be a mitogen for mesenchymal-derived cultured smooth muscle cells, fibroblasts and glial cells and to act as a chemoattractant for monocytes and neutrophils.
  • PDGF is found in the alpha granules of platelets and in endothelial cells, and has been shown to have wound-healing properties.
  • PDGF- 1 and PDGF-2 are currently produced by expression as a recombinant protein.
  • Target cells for production of PDGF- 1 and PDGF-2 include platelets, endothelial cells and cells of the monocyte/macrophage lineage.
  • Utilities for PDGF-1 and PDGF-2 include applications to the treatment of ischemic heart disease, and various research uses.
  • Angiostatin and endostatin have been observed to play a role in the inhibition of endothelial cell growth. Angiostatin and endostatin have been observed to act as inhibitors of angiogenesis in tumor bearing animals (Lannutti BJ et al, 1997; O'Reilly MS, et al, 1997).
  • Target cells for production of angiostatin and endostatin include various immune system cells.
  • Utilities for angiostatin and endostatin include applications in the treatment of cancer, and various research uses. Additional Cytokines
  • exemplary cytokines the expression of which may be increased using the methods of the invention include, but are not limited to additional family members of the above mentioned cytokines, such as the IL-6 family members oncostatin M; IL-1 1, leukemia inhibitory factor (LIF); ciliary neurotrophic factor and cardiotrophin.
  • additional family members of the above mentioned cytokines such as the IL-6 family members oncostatin M; IL-1 1, leukemia inhibitory factor (LIF); ciliary neurotrophic factor and cardiotrophin.
  • cognate receptors for the above mentioned cytokines may be increased, such as TNF soluble receptor (sTNF-R), Fas soluble receptor (sFas), and the IL-6 family receptor, soluble glycoprotein 130 (gp 130).
  • cytokines the expression of which may be increased using the methods of the invention include, but are not limited to cytokines whose genes are regulated by transcriptional factors activated by PKR, including NF- ⁇ B, IRF-1,3 and 7 and Stat family members.
  • PKR is the factor used to enhance cytokine production and the cells used in practicing the methods of the invention are capable of producing PKR and will produce a baseline level of PKR in the absence of modification.
  • PKR activity may be evaluated directly, by measuring PKR autophosphorylation activity, or the activity of the kinase in phosphorylating a substrate, preferably eukaryotic initiation factor-2 alpha (eIF-2 alpha ), or another factor such as nuclear factor-kappa B (NF- ⁇ B) (Link et al, 267 J. Biol. Chem. 239, 1992), or by a biochemical tests such as polymerase chain reaction (PCR), or Western blotting with a PKR specific antibody.
  • a substrate preferably eukaryotic initiation factor-2 alpha (eIF-2 alpha ), or another factor such as nuclear factor-kappa B (NF- ⁇ B) (Link et al, 267 J. Biol. Chem. 239, 1992), or by a biochemical tests such as polymerase chain reaction (PCR), or Western blotting with a PKR specific antibody.
  • PCR polymerase chain reaction
  • PKR expression is enhanced by a transfecting a mammalian host cell capable of producing a given cytokine with an expression vector comprising a sequence encoding PKR operably linked to a promoter and containing control sequences necessary for expression of PKR by the mammalian host cell.
  • Host cells transfected with a nucleotide sequence encoding PKR may be cultured under conditions suitable for the expression of the encoded PKR in the cells.
  • expression vectors containing polynucleotides encoding PKR can be designed such that the PKR produced by a recombinant cell may be secreted, membrane-bound, or contained intracellularly depending on the sequence and/or the vector used. In some cases, additional steps may be taken to enhance PKR expression by transfected host cells.
  • Such steps include one or more of (1) culturing the transfected cells under conditions effective to enhance PKR expression, (2) priming the PKR-transfected cells, and (3) treating the PKR-transfected cells to induce cytokine production as further described below.
  • priming and treating results in significantly enhanced cytokine production, e.g., an increase of at least 2.5-fold and preferably an increase of 10 fold or greater.
  • the methods of the invention result in an increase in cytokine production that is 100 to 1000 fold or more.
  • assays can be carried out at the protein level, the RNA level or by use of functional bioassays particular to the individual cytokine being expressed.
  • Immunoassays for a particular cytokine protein may be carried out using procedures routinely employed by those of skill in the art. Such immunoassays can be used to qualitatively and quantitatively analyze expression of a cytokine of interest.
  • a purified form of the cytokine of interest may be obtained from a natural source or produced recombinantly in transfected cells, and purified using standard techniques for protein purification.
  • the purified protein may then be used to produce either monoclonal or polyclonal antibodies specific to the expressed protein, which can be used in various immunoassays.
  • immunoassays See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Pubs., N.Y., 1988).
  • Exemplary assays include ELISA, competitive immunoassays, radioimmunoassays, Western blots, indirect immunofluorescent assays and the like.
  • Cytokine analysis kits which are also commercially available are typically used for the quantitative immunoassay of the expression level of known cytokines.
  • PKR Overexpressing Namalwa Cell Line cDNA encoding the full-length human PKR molecule (551 amino acids; Meurs, E et al, 1990; GenBank Accession No. NM_002759) was inserted into a eukaryotic expression vector, such that the PKR coding sequence was expressed under the control of the CMV promoter.
  • the vector contains various features suitable for PKR transcription, including: i) promoter sequences from the immediate early gene of the human CMV (cytomegalovirus) for high level mRNA expression; ii) polyadenylation signal and transcription termination sequences from the ⁇ -globin gene to enhance RNA stability; iii) the ampicillin resistance gene; and iv) the ColEl origin of replication for selection and maintenance in E. coli.
  • a second vector contained the ampicillin resistance gene and the ColEl origin for selection and maintenance in E. coli. and the G418 resistance marker (Neo) to allow for selection and identification of the plasmids after co-transfection into eukaryotic cells. Stable transfectants were obtained by electroporation of 4x10 6 exponentially growing
  • PKR-overexpressing and clonal Namalwa cell line was selected and designated 2A1.D1.G7. 2A1.Dl .G7 and parental Namalwa cells were cultured at 2.5x10 5 cells/ml in
  • DMEM/F12 medium supplemented with 10% FBS.
  • the cells were treated with 20 nM PMA (priming) for 20 hr followed by treatment by 200 ⁇ g/ml poly r(I):r(C) (induction) for 3 days. One set of cells was left untreated (non- induced controls). Following treatment, the culture supernatants were collected and analyzed for interleukin-6 (IL-6), interleukin-8 (IL-8), and TNF- ⁇ levels by ELISA according to the procedure provided by the supplier of the ELISA kits (R&D Systems).
  • IL-6 interleukin-6
  • IL-8 interleukin-8
  • TNF- ⁇ levels by ELISA according to the procedure provided by the supplier of the ELISA kits (R&D Systems).
  • IL-6 under various conditions is shown in Figure 1.
  • Neither the parental Namalwa nor 2 A 1.D 1.G7 cell lines produced IL-6 in the absence of the priming agent (PMA) and inducing agent [poly r(I):r(C)].
  • the parental Namalwa cells treated with PMA and poly r(I):r(C) also did not produce detectable IL-6 (in an assay with a minimum detectable level of 3 pg/ml).
  • 2A1.D1.G7 treated with PMA and poly r(I):r(C) produced greater than 300 pg/ml of IL-6.
  • Namalwa cells treated with PMA and poly r(I):r(C) also did not produce detectable IL-8 (in an assay with a minimum detectable level of 31 pg ml).
  • 2A1.D1.G7 cells treated with PMA and poly r(I):r(C) yielded approximately 300 pg/ml of IL-8, which represents at least a 10-fold increase over the untreated cells and the PMA and poly r(I):r(C) treated parental Namalwa cells.
  • several other PKR-overexpressing clonal cell lines produced between 250-470 pg/ml of IL-8 following PMA and poly r(I):r(C) treatment (data not shown).
  • TNF- ⁇ under various conditions is shown in Figure 3.
  • neither parental Namalwa nor 2A1.Dl .G7 produced TNF- ⁇ in the absence of priming and induction.
  • the parental Namalwa cell line produced approximately 800 pg/ml of TNF- ⁇ following priming and induction, while the 2A1.Dl .G7 cell line produced greater than 2000 pg/ml.
  • the PKR-overexpressing cell line produced more cytokine than the parental cell line (approximately a 2.5-fold increase) following PMA and poly r(I):r(C) treatment.
  • several other PKR-overexpressing clonal cell lines produced greater than 2000 pg/ml of TNF- ⁇ following PMA and poly r(I):r(C) treatment (data not shown).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention a trait à des procédés visant à augmenter la production de cytokines dans une culture de cellules de mammifère et ce, par le biais d'une modification du taux d'un facteur de régulation de la cytokine dans les cellules, ce qui se traduit par des niveaux accrus de production de cytokine. L'invention concerne également des lignées cellulaires présentant une expression accrue de facteur de régulation de la cytokine ainsi qu'une augmentation de l'expression de la cytokine.
EP00951042A 1999-06-15 2000-06-14 Procedes visant a augmenter la production de cytokines dans une culture cellulaire Withdrawn EP1255848A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13931399P 1999-06-15 1999-06-15
US139313P 1999-06-15
PCT/US2000/040199 WO2000077236A2 (fr) 1999-06-15 2000-06-14 Procedes visant a augmenter la production de cytokines dans une culture cellulaire

Publications (1)

Publication Number Publication Date
EP1255848A2 true EP1255848A2 (fr) 2002-11-13

Family

ID=22486056

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00951042A Withdrawn EP1255848A2 (fr) 1999-06-15 2000-06-14 Procedes visant a augmenter la production de cytokines dans une culture cellulaire

Country Status (7)

Country Link
EP (1) EP1255848A2 (fr)
JP (1) JP2003509012A (fr)
CN (1) CN1399681A (fr)
AU (1) AU6403700A (fr)
CA (1) CA2376487A1 (fr)
HK (1) HK1048650A1 (fr)
WO (1) WO2000077236A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031859A1 (en) * 1999-09-08 2001-10-18 Lau Allan S. High level cytokine production with enhanced cell viability
CN1527721A (zh) * 2000-09-12 2004-09-08 基因特罗生物治疗公司 含治疗性蛋白混合物的组合物及其生产方法
WO2002022786A1 (fr) 2000-09-14 2002-03-21 Genetrol Biotherapeutics, Inc. Procede et composition cellulaire pour composants de depistage d'une activite anti-inflammatoire
US20020115212A1 (en) * 2000-12-19 2002-08-22 Browning Laura A. Enchanced PKR expression and cytokine production
EP1844069A4 (fr) * 2005-01-28 2009-05-20 Apollo Life Sciences Ltd Molécules et leurs molécules chimériques
WO2012048298A2 (fr) 2010-10-08 2012-04-12 Caridianbct, Inc. Procédés et systèmes de culture et de récolte de cellules dans un système de bioréacteur à fibres creuses avec conditions de régulation
WO2015073918A1 (fr) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expansion de cellules dans un bioréacteur
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (fr) 2014-09-26 2016-03-31 Terumo Bct, Inc. Alimentation programmée
WO2017004592A1 (fr) 2015-07-02 2017-01-05 Terumo Bct, Inc. Croissance cellulaire à l'aide de stimuli mécaniques
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
EP3562936B1 (fr) * 2017-01-02 2024-05-22 F. Hoffmann-La Roche AG Procédé de culture de lymphocyte b
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
AU3780593A (en) * 1992-02-28 1993-09-13 Beth Israel Hospital Association, The Methods and compounds for prevention of graft rejection
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0077236A2 *

Also Published As

Publication number Publication date
CN1399681A (zh) 2003-02-26
HK1048650A1 (zh) 2003-04-11
WO2000077236A3 (fr) 2002-09-12
JP2003509012A (ja) 2003-03-11
CA2376487A1 (fr) 2000-12-21
AU6403700A (en) 2001-01-02
WO2000077236A2 (fr) 2000-12-21

Similar Documents

Publication Publication Date Title
WO2000077236A2 (fr) Procedes visant a augmenter la production de cytokines dans une culture cellulaire
CA2229405C (fr) Procede pour stimuler la production d'interferons dans une culture cellulaire
Kalina et al. IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-γ production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21
Wolvekamp et al. Interleukin-6: historical background, genetics and biological significance
Gurish et al. Cytokine mRNA are preferentially increased relative to secretory granule protein mRNA in mouse bone marrow-derived mast cells that have undergone IgE-mediated activation and degranulation
CN110959041B (zh) 促进含非天然氨基酸的蛋白质产生的方法和组合物
Lee et al. The regulation and biological activity of interleukin 12
JP3260368B2 (ja) インターロイキン−１０による腫瘍性疾患の処置
Hagiwara et al. Interleukin 1 modulates messenger RNA levels of lymphokines and of other molecules associated with T cell activation in the T cell lymphoma LBRM33-1A5.
US6864061B2 (en) Method for screening compounds for anti-inflammatory activity
Deleuran Cytokines in rheumatoid arthritis: localization in arthritic joint tissue and regulation in vitro
Turner et al. Post-transcriptional control of IL-1 gene expression in the acute monocytic leukemia line THP-1
EP1214399A1 (fr) Production de cytokine de haut niveau a viabilite cellulaire renforcee
JP2004529851A (ja) ヒトサイトカインの混合物を含む組成物およびその産生方法
SARENEVA et al. Kinetics of cytokine and NFAT gene expression in human interleukin‐2‐dependent T lymphoblasts stimulated via T‐cell receptor
Zhong et al. Transcriptional profiles during the differentiation and maturation of monocyte-derived dendritic cells, analyzed using focused microarrays
JP2004537269A (ja) 細胞の生存性の増強を伴う高レベルのサイトカイン産生
US20020115212A1 (en) Enchanced PKR expression and cytokine production
US6855519B2 (en) Methods for enhancing the production of interferon in cell culture
HK40112802A (en) Methods and compositions for promoting non-natural amino acid-containing protein production
Hara et al. Regulation of IL-3 receptor expression: evidence for a post-transcriptional mechanism that dominantly suppresses the expression of β subunits
Bamford IL-15/T receptor utilization andmRNA elements influencing its protein synthesis
HK40025639B (en) Methods and compositions for promoting non-natural amino acid-containing protein production
HK40025639A (en) Methods and compositions for promoting non-natural amino acid-containing protein production

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020115

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020115;LT PAYMENT 20020115;LV PAYMENT 20020115;MK PAYMENT 20020115;RO PAYMENT 20020115;SI PAYMENT 20020115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060314

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1048650

Country of ref document: HK